FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667087> ?p ?o ?g. }

• W4385667087 endingPage "e208218c" @default.
• W4385667087 startingPage "e208218c" @default.
• W4385667087 abstract "Background: Asciminib mechanism of action differs from other tyrosine kinase inhibitors (TKIs) for it is a Specifically Targeting the ABL Myristoyl Pocket (STAMP) ABL kinase inhibitor, that has a potential efficacy against BCR::ABL1 clones with ATP-binding site mutations, including T315I. In clinical trials in patients (pts) with Ph-positive chronic myeloid leukemia (CML) with T315I mutation, failing other TKIs, it has shown an efficacy and a good safety profile. Asciminib is in use in clinical practice in Russia in Managed Access Program (MAP) supported by Novartis Aims: To present the updated results of the asciminib use in CML patients with the T315I mutation under the MAP in 3 centers of Russia. Methods: In total 82 pts received asciminib in MAP with doses 40/200 mg BID. Twenty-nine were in a 200 mg BID dose group, the data of 24 of them are presented, while 5 pts, who undergone bone marrow transplantation, were excluded from the analysis. Twenty-three pts had T315 mutation, one patient had F317L (T315I detected, but later not confirmed). All pts were adult (>18 years) with Ph-positive CML in chronic phase (CP): 3 were in a second CP after an accelerated phase and 1 – after a blast crisis, all of them had no alternative therapeutic options. Response monitoring and toxicity control were performed according to the MAP treatment plan. Complete cytogenetic response (CCyR - corresponded to BCR::ABL1 ≤1% or MR2), major molecular response (MMR) and deep molecular response (MR4) were assessed by cumulative incident function (CIF) with Gray’s test for comparison responses in subgroups. Survival analysis was performed by Kaplan-Meier method. Results: Median (Me) age at asciminib start was 49 years (range 32-71), the female proportion was 63%. Me of CML duration before asciminib was 6,9 years (range 1-34). All pts received ≥2 prior TKIs, 45% had ≥ 4 prior TKIs. With the Me follow-up period of 21 months (range 6-39); 5 (21%) pts discontinued asciminib (4 due to resistance, 1 due to a clinician decision in achieved MR4). Nine pts had additional chromosomal abnormalities (ACAs) and/or additional BCR::ABL1 mutations in an anamnesis; their responses are presented in a table 1. Six (25%) of 24 pts had ACAs before asciminib, 4 of them achieved MMR, and one of them (№1) was resistant and lost CCyR. Six pts had additional BCR::ABL1 mutations in an anamnesis, 5 of them achieved MMR and 1 pt (№9) was resistant to therapy. Two-years overall survival at 24 months was 100%. Survival rate without treatment discontinuation was 74%. CIF of CCyR, MMR and MR4 at 24 month was 57%, 57% and 34%, respectively. Thirteen (54%) pts were ponatinib-pretreated, and CIF of MMR in ponatinib-naive pts compared to ponatinib-pretreated pts was significantly higher: 90% vs. 25% (p=0.001). In total 4 pts lost CCyR or MMR (table 1). Thirteen (54%) pts experienced adverse events (AEs) of any grade and 4 (17%) had AEs of grade 3 (neutropenia, hypercholesterinemia). No one discontinued treatment due to toxicity. Summary/Conclusion: Highly pre-treated CML pts with T315I mutation are able to achieve a response with asciminib 200 mg BID, especially in ponatinib-naive group. In our pts a safety profile was good with no evidence of severe toxicity. Asciminib shows effectiveness in highly resistant pts with T315I mutation with/without other genetic events (combined mutations, ACAs), though some of them still a challenge for clinicians. Overcoming the resistance by adding other therapy should be investigated.Keywords: Mutation status, BCR::ABL, Asciminib, Chronic myeloid leukemia" @default.
• W4385667087 created "2023-08-09" @default.
• W4385667087 creator A5000756185 @default.
• W4385667087 creator A5002853101 @default.
• W4385667087 creator A5003294629 @default.
• W4385667087 creator A5014105364 @default.
• W4385667087 creator A5014888965 @default.
• W4385667087 creator A5027497409 @default.
• W4385667087 creator A5037890159 @default.
• W4385667087 creator A5042654038 @default.
• W4385667087 creator A5043438388 @default.
• W4385667087 creator A5049490417 @default.
• W4385667087 creator A5057567314 @default.
• W4385667087 creator A5059192026 @default.
• W4385667087 creator A5078634760 @default.
• W4385667087 creator A5079236072 @default.
• W4385667087 creator A5090939168 @default.
• W4385667087 date "2023-08-01" @default.
• W4385667087 modified "2023-10-16" @default.
• W4385667087 title "P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION." @default.
• W4385667087 doi "https://doi.org/10.1097/01.hs9.0000969596.20821.8c" @default.
• W4385667087 hasPublicationYear "2023" @default.
• W4385667087 type Work @default.
• W4385667087 citedByCount "0" @default.
• W4385667087 crossrefType "journal-article" @default.
• W4385667087 hasAuthorship W4385667087A5000756185 @default.
• W4385667087 hasAuthorship W4385667087A5002853101 @default.
• W4385667087 hasAuthorship W4385667087A5003294629 @default.
• W4385667087 hasAuthorship W4385667087A5014105364 @default.
• W4385667087 hasAuthorship W4385667087A5014888965 @default.
• W4385667087 hasAuthorship W4385667087A5027497409 @default.
• W4385667087 hasAuthorship W4385667087A5037890159 @default.
• W4385667087 hasAuthorship W4385667087A5042654038 @default.
• W4385667087 hasAuthorship W4385667087A5043438388 @default.
• W4385667087 hasAuthorship W4385667087A5049490417 @default.
• W4385667087 hasAuthorship W4385667087A5057567314 @default.
• W4385667087 hasAuthorship W4385667087A5059192026 @default.
• W4385667087 hasAuthorship W4385667087A5078634760 @default.
• W4385667087 hasAuthorship W4385667087A5079236072 @default.
• W4385667087 hasAuthorship W4385667087A5090939168 @default.
• W4385667087 hasBestOaLocation W43856670871 @default.
• W4385667087 hasConcept C104317684 @default.
• W4385667087 hasConcept C126322002 @default.
• W4385667087 hasConcept C143998085 @default.
• W4385667087 hasConcept C2777583451 @default.
• W4385667087 hasConcept C2778729363 @default.
• W4385667087 hasConcept C2779536868 @default.
• W4385667087 hasConcept C2911091166 @default.
• W4385667087 hasConcept C501734568 @default.
• W4385667087 hasConcept C54355233 @default.
• W4385667087 hasConcept C71924100 @default.
• W4385667087 hasConcept C86803240 @default.
• W4385667087 hasConcept C88879693 @default.
• W4385667087 hasConceptScore W4385667087C104317684 @default.
• W4385667087 hasConceptScore W4385667087C126322002 @default.
• W4385667087 hasConceptScore W4385667087C143998085 @default.
• W4385667087 hasConceptScore W4385667087C2777583451 @default.
• W4385667087 hasConceptScore W4385667087C2778729363 @default.
• W4385667087 hasConceptScore W4385667087C2779536868 @default.
• W4385667087 hasConceptScore W4385667087C2911091166 @default.
• W4385667087 hasConceptScore W4385667087C501734568 @default.
• W4385667087 hasConceptScore W4385667087C54355233 @default.
• W4385667087 hasConceptScore W4385667087C71924100 @default.
• W4385667087 hasConceptScore W4385667087C86803240 @default.
• W4385667087 hasConceptScore W4385667087C88879693 @default.
• W4385667087 hasIssue "S3" @default.
• W4385667087 hasLocation W43856670871 @default.
• W4385667087 hasLocation W43856670872 @default.
• W4385667087 hasOpenAccess W4385667087 @default.
• W4385667087 hasPrimaryLocation W43856670871 @default.
• W4385667087 hasRelatedWork W1924236513 @default.
• W4385667087 hasRelatedWork W1967535809 @default.
• W4385667087 hasRelatedWork W2023371823 @default.
• W4385667087 hasRelatedWork W2028332702 @default.
• W4385667087 hasRelatedWork W2139973222 @default.
• W4385667087 hasRelatedWork W2184534421 @default.
• W4385667087 hasRelatedWork W2362232505 @default.
• W4385667087 hasRelatedWork W2464182413 @default.
• W4385667087 hasRelatedWork W3180515128 @default.
• W4385667087 hasRelatedWork W4253096022 @default.
• W4385667087 hasVolume "7" @default.
• W4385667087 isParatext "false" @default.
• W4385667087 isRetracted "false" @default.
• W4385667087 workType "article" @default.